Literature DB >> 7775949

Hepatitis C genotypes in haemophilic patients treated with alpha-interferon.

H Devereux1, P Telfer, G Dusheiko, C Lee.   

Abstract

The effect of alpha-interferon on the hepatitis C genotypes was examined in 25 anti-HCV-positive haemophilic patients. The rate of multiple HCV genotypes in patients who are likely to have mixed infections was also studied. Pretreatment results showed that 3/25 (12%) patients had a change in genotypes, whereas posttreatment this rose to 10/25 (40%). Seven of 10 (70%) patients who showed a change in genotype had a clinical response to alpha-interferon. Six of 25 (24%) patients showed a complete clinical response to alpha-interferon, and the majority of these were either type 2 or 3. This study supports previous evidence that type 1 is less likely to respond to alpha-interferon, and that alpha-interferon may alter the concentrations of the various circulating genotypes present in multiply-infected patients. There are many difficulties in studying hepatitis C in haemophilic patients due to the sequence heterogeneity within each individual, and this study has shown that no ideal method exists as yet for looking at HCV genotypes in multiply-infected individuals.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7775949     DOI: 10.1002/jmv.1890450308

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Multitypic hepatitis C virus infection identified by real-time nucleotide sequencing of minority genotypes.

Authors:  Andrew J Buckton; Siew-Lin Ngui; Catherine Arnold; Katie Boast; Joanne Kovacs; Paul E Klapper; Bharat Patel; Imad Ibrahim; Savita Rangarajan; Mary E Ramsay; Chong-Gee Teo
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Hepatitis C and haemophilia.

Authors:  C A Lee
Journal:  BMJ       Date:  1995-06-24

3.  Outcome of orthotopic liver transplantation in patients with haemophilia.

Authors:  F H Gordon; P K Mistry; C A Sabin; C A Lee
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.